T. Rowe Price Associates, Inc. 13D and 13G filings for Entrada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,049,572 8.200% | 39,899 (+1.33%) | Filing |
| 2024-02-14 10:03 am Sale | 2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,009,673 9.000% | -4,704 (-0.16%) | Filing |
| 2023-02-14 12:38 pm Purchase | 2022-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 3,014,377 9.600% | 993,740 (+49.18%) | Filing |
| 2022-02-14 2:35 pm Purchase | 2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA | T. Rowe Price Associates, Inc. | 2,020,637 6.400% | 2,020,637 (New Position) | Filing |